DeutschNewstral
Article
Mmarketwatch.com on 2017-12-08 13:43
Sage Therapeutics shares gain another 2% as SunTrust raises stock price target to $178 vs. $116
Related news
FDA Approves Sage Therapeutics’ Zulressowsj.com- MSage Therapeutics stock bounces 49% after positive results for depression treatmentmarketwatch.com
Sage Therapeutics, Dollar General jump; LendingClub tumblesChicago Tribune
Sage Therapeutics Takes Investors On A Wild Ride As CEO Talks Up Brain DrugsForbes- MShares of Sage Therapeutics up on Zulresso approval, but analysts expect a slow rolloutmarketwatch.com
178 schools to gain from Aspire testingArkansas Online
Cracker Barrel, Sage Therapeutics fall; Ocugen, FedEx riseSeattle Times
Sage Therapeutics surges on postpartum depression drug studyseattletimes.com- Does Sage Therapeutics' Failure Predict Its Future Results?Forbes
Sage Therapeutics CEO cashes in $35M worth of stock optionsbizjournals.com- Sage Therapeutics sees modest results from tremor drug trialbizjournals.com
- IHere’s why Sage Therapeutics fell 18% on Tuesday morninginvezz.com
- MSage Group backs guidance after revenue gainmarketwatch.com
- Weed dispensary Sage Naturals changes name after lawsuit by Sage Therapeuticsbizjournals.com
- MSage Therapeutics shares halted ahead of regulatory meeting on post-partum treatmentmarketwatch.com
- MSage Therapeutics stock surges 50% on positive trial results in postpartum depressionmarketwatch.com
- Why Sage Therapeutics' new Brier Creek center came at the perfect timebizjournals.com
- BSage Therapeutics Is Cratering Because Its Depression Treatment Failed In A Key Trialbarrons.com